Literature DB >> 23482747

The role of Notch and gamma-secretase inhibition in an ovarian cancer model.

Monjri M Shah1, Marielba Zerlin, Blake Y Li, Thomas J Herzog, Jan K Kitajewski, Jason D Wright.   

Abstract

BACKGROUND: The Notch pathway is dysregulated in ovarian cancer. We sought to examine the role of Notch and gamma-secretase (GS) inhibition in ovarian cancer.
MATERIALS AND METHODS: Established ovarian cancer cell lines were used. Quantitative polymerase chain reaction (qPCR) was used to determine the relative expression of Notch receptor and ligands. Effects of GS inhibition on proliferation, colony formation, and downstream effectors were examined via methylthiazole tetrazolium (MTT) and Matrigel assays, and qPCR, respectively. In vivo experiments with a GS inhibitor and cisplatin were conducted on nude mice. Tumors were examined for differences in microvessel density, proliferation, and apoptosis.
RESULTS: Notch3 was the most up-regulated receptor. The ligands JAGGED1 and DELTA-LIKE4 were both up-regulated. GS inhibition did not affect cellular proliferation or anchorage-independent cell growth over placebo. The GS inhibitor Compound-E reduced microvessel density in vivo.
CONCLUSION: GS inhibition does not directly affect cellular proliferation in ovarian carcinoma, but Notch pathway blockade may result in angiogenic alterations that may be therapeutically important.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23482747      PMCID: PMC3893696     

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  29 in total

1.  Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia.

Authors:  Andrew P Weng; Adolfo A Ferrando; Woojoong Lee; John P Morris; Lewis B Silverman; Cheryll Sanchez-Irizarry; Stephen C Blacklow; A Thomas Look; Jon C Aster
Journal:  Science       Date:  2004-10-08       Impact factor: 47.728

2.  Nuclear IKK activity leads to dysregulated notch-dependent gene expression in colorectal cancer.

Authors:  V Fernández-Majada; C Aguilera; A Villanueva; F Vilardell; A Robert-Moreno; A Aytés; F X Real; G Capella; M W Mayo; L Espinosa; A Bigas
Journal:  Proc Natl Acad Sci U S A       Date:  2006-12-26       Impact factor: 11.205

3.  Notch3 gene amplification in ovarian cancer.

Authors:  Joon T Park; Mei Li; Kentaro Nakayama; Tsui-Lien Mao; Ben Davidson; Zhen Zhang; Robert J Kurman; Charles G Eberhart; Ie-Ming Shih; Tian-Li Wang
Journal:  Cancer Res       Date:  2006-06-15       Impact factor: 12.701

4.  Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors.

Authors:  Oriol Casanovas; Daniel J Hicklin; Gabriele Bergers; Douglas Hanahan
Journal:  Cancer Cell       Date:  2005-10       Impact factor: 31.743

5.  Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer.

Authors:  Stephen A Cannistra; Ursula A Matulonis; Richard T Penson; Julie Hambleton; Jakob Dupont; Howard Mackey; Jeffrey Douglas; Robert A Burger; Deborah Armstrong; Robert Wenham; William McGuire
Journal:  J Clin Oncol       Date:  2007-11-20       Impact factor: 44.544

6.  Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study.

Authors:  Robert A Burger; Michael W Sill; Bradley J Monk; Benjamin E Greer; Joel I Sorosky
Journal:  J Clin Oncol       Date:  2007-11-20       Impact factor: 44.544

Review 7.  Notch and cancer: a double-edged sword.

Authors:  U Koch; F Radtke
Journal:  Cell Mol Life Sci       Date:  2007-11       Impact factor: 9.261

8.  Normalization of gene expression measurements in tumor tissues: comparison of 13 endogenous control genes.

Authors:  Jacques B de Kok; Rian W Roelofs; Belinda A Giesendorf; Jeroen L Pennings; Erwin T Waas; Ton Feuth; Dorine W Swinkels; Paul N Span
Journal:  Lab Invest       Date:  2005-01       Impact factor: 5.662

9.  Integrated genomic analyses of ovarian carcinoma.

Authors: 
Journal:  Nature       Date:  2011-06-29       Impact factor: 49.962

10.  The Notch pathway in ovarian carcinomas and adenomas.

Authors:  O Hopfer; D Zwahlen; M F Fey; S Aebi
Journal:  Br J Cancer       Date:  2005-09-19       Impact factor: 7.640

View more
  8 in total

Review 1.  The Role of Notch3 in Cancer.

Authors:  Zviadi Aburjania; Samuel Jang; Jason Whitt; Renata Jaskula-Stzul; Herbert Chen; J Bart Rose
Journal:  Oncologist       Date:  2018-04-05

Review 2.  Estrogen signaling crosstalk: Implications for endocrine resistance in ovarian cancer.

Authors:  Jennifer R Ribeiro; Richard N Freiman
Journal:  J Steroid Biochem Mol Biol       Date:  2014-02-22       Impact factor: 4.292

3.  Predicting Novel Therapies and Targets: Regulation of Notch3 by the Bromodomain Protein BRD4.

Authors:  Jason Roszik; Anil K Sood; Alejandro Villar-Prados; Sherry Y Wu; Karem A Court; Shaolin Ma; Christopher LaFargue; Mamur A Chowdhury; Margaret I Engelhardt; Cristina Ivan; Prahlad T Ram; Ying Wang; Keith Baggerly; Cristian Rodriguez-Aguayo; Gabriel Lopez-Berestein; Shyh Ming-Yang; David J Maloney; Makoto Yoshioka; Jeffrey W Strovel
Journal:  Mol Cancer Ther       Date:  2018-11-12       Impact factor: 6.261

4.  Live tumor imaging shows macrophage induction and TMEM-mediated enrichment of cancer stem cells during metastatic dissemination.

Authors:  Ved P Sharma; Binwu Tang; Yarong Wang; Camille L Duran; George S Karagiannis; Emily A Xue; David Entenberg; Lucia Borriello; Anouchka Coste; Robert J Eddy; Gina Kim; Xianjun Ye; Joan G Jones; Eli Grunblatt; Nathan Agi; Sweta Roy; Gargi Bandyopadhyaya; Esther Adler; Chinmay R Surve; Dominic Esposito; Sumanta Goswami; Jeffrey E Segall; Wenjun Guo; John S Condeelis; Lalage M Wakefield; Maja H Oktay
Journal:  Nat Commun       Date:  2021-12-15       Impact factor: 14.919

Review 5.  The role of Notch signaling in the mammalian ovary.

Authors:  Dallas A Vanorny; Kelly E Mayo
Journal:  Reproduction       Date:  2017-03-10       Impact factor: 3.906

6.  Notch3 overexpression associates with poor prognosis in human non-small-cell lung cancer.

Authors:  Yuan-zi Ye; Zhi-hong Zhang; Xiao-yun Fan; Xiao-lan Xu; Mei-li Chen; Bo-wen Chang; Yan-bei Zhang
Journal:  Med Oncol       Date:  2013-05-07       Impact factor: 3.064

Review 7.  Notch signaling in serous ovarian cancer.

Authors:  Jolijn W Groeneweg; Rosemary Foster; Whitfield B Growdon; René H M Verheijen; Bo R Rueda
Journal:  J Ovarian Res       Date:  2014-11-04       Impact factor: 4.234

8.  miR‑1299/NOTCH3/TUG1 feedback loop contributes to the malignant proliferation of ovarian cancer.

Authors:  Yuqing Pei; Kexin Li; Xiaoying Lou; Yue Wu; Xin Dong; Wenpeng Wang; Ning Li; Donghong Zhang; Wei Cui
Journal:  Oncol Rep       Date:  2020-05-25       Impact factor: 3.906

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.